IHS Chemical Week

Regions :: North America :: U.S.

Bayer enters into collaboration with Seattle Genetics for development of anticancer drugs

12:07 AM MDT | June 26, 2013 | Deepti Ramesh

Bayer says that its Bayer HealthCare subgroup has entered into a new antibody-drug conjugate (ADC) collaboration with biotechnology company Seattle Genetics (Bothell, WA). Bayer, under the deal, will get worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets. Under the terms of the agreement, Bayer will be responsible for research, product development, manufacturing, and commercialization of all products. In addition to an upfront payment and option exercise fees of up to $20 million...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa